In one study the concurrent use of
atovaquone and
rifabutin resulted in a 34% decrease in the AUC of
atovaquone and a small 19% decrease in
rifabutin levels.
It has been suggested that no
atovaquone dosage adjustment is needed. However, in the UK, the manufacturer of
atovaquone still considers that
rifabutin use could result in subtherapeutic
atovaquone levels and so they advise against the use of this combination.